Thursday, June 27, 2024
Medasense, a global leader in pain monitoring solutions, is excited to announce an exclusive partnership with Nihon Kohden for the distribution of its advanced pain monitoring device in Japan.
This collaboration is set to revolutionize pain management practices in Japanese healthcare facilities, significantly enhancing patient care.
High-quality and innovative medical technology, is joining forces with Medasense to bring the nociception monitor to the Japanese market. This state-of-the-art device, featuring the AI-powered NOL - Nociception Level Index®, provides real-time, objective pain monitoring, enabling personalized and optimized pain treatment.
It will be available to hospitals and clinics across Japan through Nihon Kohden's extensive distribution network, pending regulatory approval.
"Partnering with Nihon Kohden, a company with a long history of excellence that shares our vision for improving patient care through innovative solutions, is an honor. Our mission is to reduce patients' pain and the adverse effects of pain medication.
Nihon Kohden's established clinical and technological leadership in the Japanese market makes them the ideal partner for distributing our nociception monitor."
The NOL monitoring system provides an AI-powered, clinically validated index to objectively measure the physiological response to pain (nociception), assisting clinicians in delivering personalized anesthesia tailored to individual patient needs.
With over 40 peer-reviewed publications, clinical studies have demonstrated that NOL-guided analgesia leads to intraoperative opioid reduction and improved postoperative pain scores and recovery.
Source: prnewswire.com
